Despite substantial evidence supporting the use of GLP-1 receptor agonists (GLP-1RAs) and SGLT2i in patients with T2DM, their prescription rates remain conspicuously low within this cohort. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.